Neil Kumar, BridgeBio CEO
May 13, 2022 07:33 AM EDT
Deals
Bioregnum

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

With­in hours of is­su­ing word that Bridge­Bio $BBIO had pulled in $90 mil­lion from its SHP2 li­cens­ing deal with Bris­tol My­ers Squibb, CEO Neil Ku­mar …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

France stops Val­neva's chikun­gun­ya vac­cine roll­out in over 65s af­ter safe­ty is­sue

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times